Kyoto Startup to Begin Clinical Trial of iPSC-Derived Platelet Agent This Year, Eyes 10 Billion Yen Biz

Megakaryon President Kenichi Akamatsu Kyoto-based biotech upstart Megakaryon will initiate a clinical trial of an iPS cell-derived platelet preparation later this year, aiming to obtain Japanese regulatory approval in the second half of 2023 or soon after, President Kenichi Akamatsu...read more